NIH-funded research R21 grant

PEDF-enriched urine-derived stem cell sheets for corneal healing after sulfur mustard injury

Official title: PEDF-enriched Urine-derived Stem Cell Sheets for Corneal Wound Healing in Mustard Gas Injury

Funded at Wake Forest University Health Sciences · NIH-11335528 · Data updated 2026-11-12

A new therapy using a patient’s own urine-derived stem cells engineered to release PEDF aims to heal corneal wounds caused by sulfur mustard exposure.

More Wound research and trials

Quick facts

Grant typeR21 grant
Study typeNIH-funded research
Funding institutionWake Forest University Health Sciences
NIH-funded
Lab location1 site (Winston-Salem, United States)
Project startAugust 1, 2026
Project endJuly 31, 2028
Funding year2026
Award (this year)$426,250
NIH project number1R21EY037262-01A1
Project IDNIH-11335528 on NIH RePORTER

Who could benefit from this research

Could help

Adults with sulfur mustard–related chronic corneal injury who are eligible for autologous cell-based therapy.

Less likely to help

Patients without corneal injury or without access to autologous urine-derived cells may not benefit from this approach.

What this research studies

This project uses a patient-specific, non-invasive source of stem cells obtained from urine to create a sheet of corneal cells, enhanced with pigment epithelium-derived factor to promote healing. The approach seeks to overcome limitations of current stem cell options by avoiding invasive harvesting and reducing tumor risk. It combines autologous cell sheets with sustained PEDF delivery to support epithelial regeneration and limit inflammation and scarring in sulfur mustard–related corneal injury.

Why it matters

Potential benefit: If successful, patients could experience faster, more reliable corneal healing with better vision outcomes and fewer complications after chemical injury.

How similar studies have gone: Preliminary work has shown autologous USC-derived epithelial sheets can form functional layers and support healing in ocular contexts, with favorable safety signals.

Where this research is happening

  • Wake Forest University Health Sciences
    Winston-Salem, United States
    Active

Researchers

  • Principal investigator: Zhang, Yuanyuan No — Wake Forest University Health Sciences
  • Study coordinator: Zhang, Yuanyuan No

Related research

Other NIH-funded projects on the same topics.

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.